Defunct Company
Total Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
100
NCT02401542
Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jun 30, 2015
Completion: Nov 1, 2019
NCT02925533
Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Phase: Phase 1
Role: Collaborator
Start: Dec 14, 2016
Completion: Jun 30, 2017
NCT03123055
A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Start: Apr 20, 2017
Completion: Dec 1, 2019